Please login to the form below

Not currently logged in
Email:
Password:

NASH

This page shows the latest NASH news and features for those working in and with pharma, biotech and healthcare.

FDA delays decision on Intercept's NASH drug by three months

FDA delays decision on Intercept's NASH drug by three months

As it stands, Intercept is poised to access the NASH market before its larger rivals but it is unclear if that first-mover advantage will translate into commercial success. ... Diagnosis is another potential barrier to sales growth. NASH is definitively

Latest news

More from news
Approximately 26 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Keeping up the fight against HIV and using the lessons to tackle other threats Keeping up the fight against HIV and using the lessons to tackle other threats

    Gilead, which has suffered two recent NASH therapy trial knock-backs, believes medical and scientific advances need to be welded to comprehensive patient engagement to engineer effective responses to what is ... being labelled as the next public health

  • Deal Watch October 2018

    treatments for NASH with Pfizer products. Not. disclosed. One of the big deals for Novartis these last two months was the long‐rumoured sale of it’s Sandoz division’s US ... The agreement is driven by the belief that liver diseases will respond

  • Taking a lean and careful approach Taking a lean and careful approach

    A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what else we can come up with there.”. ... The NASH market is expected to be worth $20bm by 2025 and financial brokers recently valued

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Oncology, immuno-oncology and central nervous system therapies once again topped the charts, but 2016 also saw the emergence of new areas, notably non-alcoholic steatohepatitis or NASH. ... With NASH appearing to be a long-term consequence of obesity it

  • Deal Watch December 2016 Deal Watch December 2016

    The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small molecules in the field of chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, non-alcoholic steato-hepatitis (NASH),

More from intelligence
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics